Key Highlights
• Doximity shares surged approximately 32.58 percent to $27.39, a gain of $6.73 from a prior close of $20.66, and rose further to $27.95 in after-hours trading.
• Fiscal first quarter 2027 results showed revenue of $157.1 million, up 7 percent year over year, beating the high end of guidance, with adjusted EBITDA margin of 48 percent beating guidance by 9 percent.
• Non-GAAP gross margin compressed slightly to 90 percent from a higher prior-year level, which the company attributed to AI compute spend, though the company raised full-year guidance meaningfully.
• An independent study by Stanford and Harvard researchers ranked Doximity AI Search as the top clinical AI model, with a 4.8 percent error rate versus Anthropic's best model, attributed to expert-verified drug reference content and over 12,000 physician peer-review editors.
Fiscal Q1 Beat and AI Search Momentum
Doximity, Inc. (NYSE:DOCS) shares closed up 32.58 percent at $27.39, with CEO Jeff Tangney touting the company's clinical AI Search product and highlighting outsized economics from its AI Search product. Fiscal first quarter 2027 revenue reached $157.1 million, up 7 percent year over year, beating the high end of guidance, with an adjusted EBITDA margin of 48 percent beating guidance by 9 percent.
An independent study by Stanford and Harvard researchers ranked Doximity AI Search as the top clinical AI model with a 4.8 percent error rate, versus 13.6 percent for the next best model, attributed to a built-in, expert-verified drug reference and over 12,000 physician peer-review editors. The company now houses the largest health system AI client base, including Northwestern, Penn Medicine, and around 165 signed health system AI clients.
Usage Growth and Guidance Raise
Usage growth was strong, with active workflow prescribers up 30 percent year over year, nearly half using AI tools. Doximity Scribe note-taking users grew 10 times in the last year, with the company aiming to be three-way in both search and clinical AI.
Guidance was raised: full-year fiscal 2027 revenue guidance raised to $671 million to $681 million, from a prior range implying 5 percent growth at the midpoint, and adjusted EBITDA guidance raised to $305 million to $315 million, reflecting continued heavy investment in clinical AI compute and increased cost of demand, with gross margins expected to trend mid-90s for the year.
What Investors May Watch Next
Market participants are likely to watch how the AI search product's usage and revenue contribution scale in coming quarters, particularly as the company faces year-ago comparisons. Client engagement metrics, including the majority of active clients with no revenue recognized to date in Q1, may factor into how analysts and investors view the near-term revenue outlook against the longer-term AI strategy.
The company's balance sheet, with $688 million in cash, no debt, and continued repurchase activity under its buyback program with $400 million remaining, may also be a factor investors weigh alongside growth execution.
Conclusion
In summary, Doximity (NYSE:DOCS) shares rose approximately 32.58 percent to $27.39 at last closing, driven by a fiscal first quarter beat, an independent study ranking its AI Search product as a top clinical AI model, and raised full-year guidance. These are the verified facts from the earnings release and market data. Whether the rally proves durable may depend on how quickly the AI Search product's usage translates into recognized revenue.



_11_17_2026_10_00_22_634482.jpg)


Please wait processing your request...